摘要
目的:观察米非司酮配伍桂枝茯苓丸治疗子宫肌瘤的临床效果。方法:将绝经前有症状的子宫肌瘤患者79例随机分为治疗组和对照组,其中治疗组40例,米非司酮5 mg、桂枝茯苓丸6丸口服,每日1次;对照组39例,米非司酮5 mg口服,每日1次;两组从月经周期第1天开始,连服3个月。在治疗前后B超测量子宫体积,行子宫内膜病检,观察子宫内膜变化;检测治疗前后雌孕激素,血红蛋白水平,肝、肾功能,观察服药后的不良反应,并按期随访。结果:两组患者治疗期间均闭经,子宫内膜及雌孕激素水平维持于增殖早期,血红蛋白上升。两组治疗后子宫体积、最大肌瘤的平均体积缩小,治疗组子宫和最大肌瘤体积缩小较多,两组间差异有统计学意义(P<0.01)。两组不良反应类似且无需特殊处理,停药后多数患者月经逐渐恢复,肌瘤复发。结论:米非司酮配伍桂枝茯苓丸治疗子宫肌瘤优于单纯应用米非司酮治疗,适于术前或围绝经期用药,但仍无法替代手术治疗。
Objective：To observe the effect of low-dose mifepristone combined with Keishibukuryogan on hysteromyoma.Methods：79 symptomatic patients with hysteromyoma were divided into 2 groups randomly.Control group（39 cases） received mifepristone,5 mg per day and treated group（40 cases） received mifepristone per day combined with Keishibukuryogan,6 bolus per day,the therapies started from the first day of menstrual cycle for three months.Uterine size was measured by B ultrasound before and after treatment,pathological examination was conducted on endometrium and the changes of hysteromyoma were recorded;the levels of estrogen,progesterone,hemoglobin and liver function,renal function before and after treatment were detected;adverse reactions after treatment were observed;follow up was carried out.Results：All the patients in the two groups were amenorrhea with increased hemoglobin level,the level of estrogen and progesterone remained at the early stage of proliferation phase.The uterus and hysteromyoma sizes in two groups both reduced,but those in treated group reduced significantly（P〈0.01）.Adverse reactions showed similarity and needed no special treatments,recovery of menstruation and hysteromyoma occurred in most of patients after termination of therapies.Conclusion：The effect of low-dose mifepristone combined with Keishibukuryogan on hysteromyoma is superior to that of simple mifepristone,mifepristone combined with Keishibukuryogan is suitable for preoperative and perimenopausal treatment,but cann＇t be replaced surgery.
出处
《中国妇幼保健》
CAS
北大核心
2009年第30期4311-4312,共2页
Maternal and Child Health Care of China
